$74.19
Today
as of Sep 4, 16:52 ET
Last 30 days
Recent Press Releases & News
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar’s (NKTR) Billion-Dollar Balance Sheet Faces A Multi-Year Test
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Overview
52-week range
$33
$109
54% of range
Avg surprise (last 3)
-7.0%
Avg reaction (last 2)
-0.2%
50% positive
Latest IV / EM
74%
EM ±11.6% · $75 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-1.23 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $-1.82 | $-1.74 | -4.6% | -727.3% | -2.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.87 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-2.95 | $-3.13 | +5.8% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.22 | $-0.18 | -22.2% | — | +1.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-2.66 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-3.76 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.19 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.24 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.27 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.73 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $11M | — | $12M | $11M | $10M | — | $24M |
| Cost of revenue | — | — | — | $0 | $0 | $0 | — | $4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-42M | $-39M | — | $-32M | $-36M | $-45M | — | $-34M |
| Net income | $-41M | $-45M | — | $-36M | $-42M | $-51M | — | $-37M |
| EPS (diluted) | $-1.23 | $-1.82 | — | $-1.87 | $-2.95 | $-3.62 | — | $-2.66 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $39M | $150M | $15M | $41M | $43M | $39M | $44M | $30M |
| Inventory | — | — | — | — | — | — | — | $0 |
| Total current assets | $739M | $589M | $266M | $281M | $187M | $230M | $261M | $286M |
| Total assets | $1.10B | $763M | $280M | $301M | $208M | $256M | $304M | $308M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $192M | $187M | $191M | $216M | $232M | $243M | $243M | $259M |
| Total equity | $903M | $576M | $90M | $85M | $-24M | $14M | $61M | $49M |